您好,欢迎您
直肠腺癌的最佳管理:现状与未来展望
In locally advanced CRM+ve or very low primary: Long course CRT + adjuvant chemo if still N+ (or was N+ve on scans but now ypN0) In operable high risk: Use EMVI: FOLFOX pre CRT or pre op? In metastatic rectal adenocarcinoma: Operable: chemo +/- biological first Inoperable: chemo + biological first (EGFRi if RAS all WT) Near future: Total neoadjuvant therapy for high risk operable cases? Optimisation of all stage outcomes with liquid biopsies?

尊敬的用户,免费试读已结束啦
1积分 即可解锁全文
我要解锁全文
兑换后可在APP分享给 3 位好友免费读
全屏
1/5
1积分解锁全文
立即下载
热门推荐
查看更多>>
全屏
1/5
1积分解锁全文
立即下载